Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted its…
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development…
SeaSpine® Announces Exclusive Development and Licensing Agreement with restor3D®
September 24, 2019 CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it…
Duke University & Deerfield Management Announce Four Points Innovation
Deerfield Commits up to $130 million to Accelerate Drug Discovery at Duke Through a Newly Launched Company Visit Four Points Innovation (Durham, NC and New York, NY, December 18, 2019)—Duke University and Deerfield Management Company, a healthcare investment firm, today announced the creation of…
Bandage heals broken bones by trapping a biochemical
When a bone-break occurs, the body floods the injury site with a healing biochemical known as adenosine. A new bandage is designed to absorb that substance, keeping it around so it can do more work.…
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced updated interim clinical data from the ongoing Phase 1 trial of its…
LUMEDICA VISION RANKED THIRD MOST FUNDABLE COMPANY IN AMERICA
Lumedica Inc., a privately held company focused on improving access to eye care by creating low-cost, high performance, Optical Coherence Tomography (OCT) systems for research and clinical applications, was awarded Third Place in Pepperdine University’s…
MassChallenge startup competition winner uses breast milk to fight cerebral palsy
A North Carolina startup that uses molecules from breast milk to help prevent cerebral palsy took home a $100,000 grant Thursday night, the top prize in the annual awards program carried out by MassChallenge, a…
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patient has been dosed in a Phase 2b clinical trial…